Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2 DOI Creative Commons
Haibo Wu, Na Xing, Kaiwen Meng

et al.

Cell Host & Microbe, Journal Year: 2021, Volume and Issue: 29(12), P. 1788 - 1801.e6

Published: Nov. 13, 2021

Previous work found that the co-occurring mutations R203K/G204R on SARS-CoV-2 nucleocapsid (N) protein are increasing in frequency among emerging variants of concern or interest. Through a combination silico analyses, this study demonstrates adaptive, while large-scale phylogenetic analyses indicate associate with emergence high-transmissibility lineage B.1.1.7. Competition experiments suggest 203K/204R possess replication advantage over preceding R203/G204 variants, possibly related to ribonucleocapsid (RNP) assembly. Moreover, virus shows increased infectivity human lung cells and hamsters. Accordingly, we observe positive association between COVID-19 severity sample 203K/204R. Our suggests contribute transmission virulence select variants. In addition spike protein, important for viral spreading during pandemic.

Language: Английский

The biological and clinical significance of emerging SARS-CoV-2 variants DOI Creative Commons
Kaiming Tao, Philip L. Tzou, Janin Nouhin

et al.

Nature Reviews Genetics, Journal Year: 2021, Volume and Issue: 22(12), P. 757 - 773

Published: Sept. 17, 2021

Language: Английский

Citations

993
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses DOI Creative Commons
Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(3), P. 467 - 484.e15

Published: Jan. 4, 2022

On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, failed to neutralize. Titers against boosted third vaccine doses high both vaccinated individuals those Delta. Mutations knock out reduce neutralization most large panel potent monoclonal antibodies under commercial development. S has structural changes earlier viruses uses that confer tight binding ACE2 unleash evolution driven immune escape. This leads number site rebalances receptor affinity viruses.

Language: Английский

Citations

936
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review DOI Creative Commons
Thibault Fiolet, Yousra Kherabi,

Conor-James MacDonald

et al.

Clinical Microbiology and Infection, Journal Year: 2021, Volume and Issue: 28(2), P. 202 - 221

Published: Oct. 27, 2021

Language: Английский

Citations

837
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum DOI Creative Commons
Chang Liu, Helen M. Ginn, Wanwisa Dejnirattisai

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(16), P. 4220 - 4236.e13

Published: June 17, 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 contributed to the current wave of infection ravaging Indian subcontinent and been designated a concern in United Kingdom. Here we study ability monoclonal antibodies convalescent vaccine sera neutralize B.1.617.1 B.1.617.2, complement this structural analyses Fab/receptor binding domain (RBD) complexes, map antigenic space variants. Neutralization both viruses is reduced compared ancestral Wuhan-related strains, but there no evidence widespread antibody escape as seen B.1.351. However, B.1.351 P.1 showed markedly more reduction neutralization suggesting that individuals infected previously by these may be susceptible reinfection B.1.617.2. This observation provides important new insights for immunization policy future vaccines non-immune populations.

Language: Английский

Citations

713
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum DOI Creative Commons
Aekkachai Tuekprakhon, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(14), P. 2422 - 2433.e13

Published: June 9, 2022

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number sublineages. BA.1 dominated the initial wave but been replaced by BA.2 many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 BA.5, are taking over locally, driving wave. BA.5 contain identical spike sequences, although closely related BA.2, they further mutations receptor-binding domain their spikes. Here, we study neutralization BA.4/5 using range vaccine naturally immune serum panels monoclonal antibodies. shows reduced individuals vaccinated with triple doses AstraZeneca or Pfizer compared BA.2. Furthermore, breakthrough infections, there are, likewise, significant reductions BA.4/5, raising possibility repeat infections.

Language: Английский

Citations

677
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence DOI Creative Commons
Felipe Gomes Naveca, Valdinete Alves do Nascimento, Victor Costa de Souza

et al.

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(7), P. 1230 - 1238

Published: May 25, 2021

Language: Английский

Citations

433
SARS-CoV-2 Variants in Patients with Immunosuppression DOI Open Access
Lawrence Corey,

Chris Beyrer,

Myron S. Cohen

et al.

New England Journal of Medicine, Journal Year: 2021, Volume and Issue: 385(6), P. 562 - 566

Published: Aug. 4, 2021

SARS-CoV-2 and Immunosuppression In this article, the authors discuss challenges of infection in patients with a weakened immune system, including potential implications regardin...

Language: Английский

Citations

416
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants DOI Creative Commons
Kathryn Westendorf,

Stefanie Žentelis,

Lingshu Wang

et al.

Cell Reports, Journal Year: 2022, Volume and Issue: 39(7), P. 110812 - 110812

Published: April 25, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants concern (VOCs) have negatively affected therapeutic use some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), highly potent spike glycoprotein receptor binding domain (RBD)-specific antibody. potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, variants, including B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, BA.2 subvariant. Structural analysis reveals that contact residues epitope are conserved, except for N439 N501. The neutralizing activity is unaffected by most common mutations at these positions (N439K N501Y). broad relatively conserved suggest has potential to be an effective agent treat all known variants.

Language: Английский

Citations

402
After the pandemic: perspectives on the future trajectory of COVID-19 DOI Creative Commons
Amalio Telenti, Ann M. Arvin, Lawrence Corey

et al.

Nature, Journal Year: 2021, Volume and Issue: 596(7873), P. 495 - 504

Published: July 8, 2021

There is a realistic expectation that the global effort in vaccination will bring pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control. Nonetheless, uncertainties remain about type of long-term association virus establish with human population and, particular, whether disease 2019 (COVID-19) become an endemic disease. Although trajectory difficult to predict, conditions, concepts and variables influence this transition can be anticipated. Persistence SARS-CoV-2 as virus, perhaps seasonal epidemic peaks, may fuelled pockets susceptible individuals waning immunity after infection or vaccination, changes through antigenic drift diminish protection re-entries from zoonotic reservoirs. Here we review relevant observations previous epidemics discuss potential evolution it adapts during persistent transmission presence level immunity. Lack effective surveillance adequate response could enable emergence new patterns SARS-CoV-2. are key pieces data urgently needed order make good decisions; outline these propose way forward. This Perspective discusses possible future infection, development variants, spread implications for vaccine deployment consequences issues policy.

Language: Английский

Citations

399
Tackling COVID-19 with neutralizing monoclonal antibodies DOI Creative Commons
Davide Corti, Lisa A. Purcell,

Gyorgy Snell

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(12), P. 3086 - 3108

Published: May 26, 2021

Language: Английский

Citations

373